|Bid||10.02 x 1400|
|Ask||10.02 x 1000|
|Day's Range||10.00 - 10.07|
|52 Week Range||9.60 - 17.47|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Two special purpose acquisition companies announced mergers with space companies Monday. Spire Global, for starters, is merging with the SPAC (NSH)(ticker: NSH). Spire is a data provider to global companies.
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Osprey Technology Acquisition Corp. ("SFTW" or the "Company") (SFTW) relating to its proposed merger with BlackSky Holdings, Inc. Under the terms of the agreement, SFTW will merge into BlackSky, with BlackSky emerging as a publicly traded company.
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Osprey Technology Acquisition Corp. (NYSE: SFTW) Osprey Technology Acquisition Corp. has agreed to merge with BlackSky Holdings. Under the proposed transaction, Osprey Technology shareholders will own only 21% of the combined company. PRA Health Sciences, Inc. (NASDAQ: PRAH) PRA Health Science has agreed to be acquired by ICON plc. Under the proposed transaction, shareholders of PRA will receive 0.4125 shares of ICON common stock and $80.00 in cash per share. Reinvent Technology Partners (NYSE: RTP) Reinvent Technology Partners has agreed to merge with oby Aviation. Under the proposed transaction, Reinvent Technology shareholders will own just 10% of the combined company. Pandion Therapeutics, Inc. (NASDAQ: PAND) Pandion Therapeutics has agreed to be acquired by Merck. Under the proposed transaction, shareholders of Pandion will receive $60.00 per share. Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process. Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at firstname.lastname@example.org or telephone at (212) 709-8245. The consultation and case are free with no obligation to you. Moore Kuehn pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Moore Kuehn is a 5-star Google rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please visit http://www.moorekuehn.com/practice/new-york-securities-litigation/. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts:Moore Kuehn, PLLCJustin Kuehn, Esq.30 Wall Street, 8th FloorNew York, New York email@example.com(212) 709-8245